CRESCENT BIOPHARMA, INC. (CBIO) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN USG2545C1048
CRESCENT BIOPHARMA, INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 10.84 m USD |
| Operating income | -152.63 m USD |
| EBIT | -149.76 m USD |
| Net income | -153.94 m USD |
Full history since 2011, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About CRESCENT BIOPHARMA, INC.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
More stocks
- YungShin Global Holding Corp (3705.TW)
- Comp SA (CMP.WA)
- Hubei Xiangyuan New Material Technology Inc. (300980.SZ)
- Zhejiang Yatai Pharmaceutical Co Ltd (002370.SZ)
- Atria Oyj (ATRAV.HE)
- Heren Health Co Ltd (300550.SZ)
- Zhejiang Zhengte Co Ltd (001238.SZ)
- CHO Pharma Inc. (6586.TWO)
- First Farmers Financial Corp (FFMR)
- Mears Group PLC (MER.L)
- Anhui Jinchun Nonwoven Co Ltd (300877.SZ)
- IVU Traffic Technologies (IVU.DE)
Not investment advice. All data without warranty, price as of 09.11.2026. Details in the risk notice.